Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human test of new gene therapy for devastating muscle disease

NCT ID NCT06114056

Summary

This early-stage study is testing the safety and initial effects of a single dose of an experimental gene therapy called JWK007 in boys with Duchenne muscular dystrophy (DMD). The trial will enroll only 3 boys aged 5-10 years to receive a low-dose injection. The main goal is to see if the treatment is safe and well-tolerated, while also checking for any early signs of improvement in muscle function.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.